Sabby Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Sabby Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,985	Closed	-$492K	–	306
2016 Q3	$492K	Sell	1,985 -2,640	-57%	-$966K	0.02%	226
2016 Q2	$4.13M	Sell	4,625 -389	-8%	-$429K	0.22%	63
2016 Q1	$4.56M	Buy	+5,014	New	+$4.92M	0.23%	47
2015 Q4	–	Sell	-4,039	Closed	-$6.77M	–	336
2015 Q3	$6.77M	Buy	4,039 +3,249	+411%	+$6.69M	0.28%	59
2015 Q2	$1.7M	Buy	+790	New	+$1.53M	0.06%	182

Other funds holding ELDN

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sabby Management's ELDN Position: Q4 2016 in Review

Sabby Management sold out of Eledon Pharmaceuticals (ELDN) in Q4 2016, closing a stake of 1,985 shares — an estimated $492K sold.

Sabby Management first reported a position in ELDN in Q2 2015 and held it in 5 quarters. The position peaked at $6.77M in Q3 2015. 42 funds tracked by Wall St. Rank hold ELDN as of Q4 2016.

Sabby Management reported no remaining Eledon Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Sabby Management sold 1,985 Eledon Pharmaceuticals shares in Q4 2016, an estimated $492K.
Sabby Management first reported a position in Eledon Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Sabby Management's Eledon Pharmaceuticals position peaked at $6.77M in Q3 2015.
42 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2016.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.